DELETE All INSTRUCTIONS AND COMMENTS

Read these instructions carefully before starting

As you are finishing this document, **remove these instructions**, delete all the template language (in dark orange) so that they are not contained in the final version of your protocol.

Delete sections that do not apply to your study. **If removing sections of this protocol**, update the table of contents by right-clicking on it and selecting “update field”.

* **What template should I use?**
  + This template is for studies involving interviews, surveys, focus groups, or behavioral interventions
  + If unsure whether IRB review is required for your project, please start by [using our website tool](http://irb.emory.edu/forms/review/index.html) under “Does My Project Need IRB Review?”
  + For studies involving clinical procedures or tests for research purposes you must use the [Biomedical](http://irb.emory.edu/forms/Study%20Submission.html) protocol template. The only exception is for behavioral studies where the only collected sample is obtained via a non-invasive method (for example saliva for cortisol tests).
  + For studies involving secondary data analysis only, please use the “[Secondary Analysis Protocol](http://irb.emory.edu/forms/Study%20Submission.html)**”** templateinstead**.**
  + For studies involving solely a review of medical charts, please see the “[Retrospective Chart Review Protocol](http://irb.emory.edu/forms/Study%20Submission.html)” template instead.
* **You must complete below** the [Sociobehavioral Protocol Checklist](#_Protocol_Checklist) with your protocol, to attest that you have considered all the required sections in this template.
* Grant applications normally **may** **not** be submitted to the IRB instead of a protocol document
* When you write this document, keep an electronic copy. You will need to modify this copy when making changes. You should **upload** the modified copy of your protocol instead of **adding a new version**.

**PROTOCOL TITLE**: Include the full protocol title. (Add your text)

**EXTERNAL (NON-EMORY) COLLABORATORS**

Name, Title(s), Institution, and Department of External Collaborators

(For each entry, please indicate whether that institution’s IRB will review (or has already reviewed) that individual’s engagement in human participants research activities)

(Add your text)

**PRINCIPAL INVESTIGATOR:**

Name (Add your text)

Department (Add your text)

Telephone Number (Add your text)

Email Address (Add your text)

**VERSION**: **ADD** (Add your text)

**FUNDING SOURCE**: Include the information for the funding entity for this study. Please explain if this study is covered by a sub-award or other pertinent information. (Add your text)

**REVISION HISTORY**

No need to review this section if this is the first version of the protocol you are submitting to the IRB

|  |  |  |
| --- | --- | --- |
| **Revision #** | **Version Date** | **Summary of Changes** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

Table of Contents

[1. Study Summary 5](#_Toc125966858)

[2. Objectives 5](#_Toc125966859)

[3. Background 5](#_Toc125966860)

[4. Study Endpoints 6](#_Toc125966861)

[5. Study Intervention/Design 6](#_Toc125966862)

[6. Procedures Involved 6](#_Toc125966863)

[7. Data Specimen Banking 7](#_Toc125966864)

[8. Sharing of Results with Participants 7](#_Toc125966865)

[9. Study Timelines 7](#_Toc125966866)

[10. Inclusion and Exclusion Criteria 8](#_Toc125966867)

[11. Population 8](#_Toc125966868)

[12. Local Number of Participants 9](#_Toc125966870)

[13. Recruitment Methods 9](#_Toc125966871)

[14. Withdrawal of Participants 10](#_Toc125966872)

[15. Risk to Participants 10](#_Toc125966873)

[16. Potential Benefits to Participants 10](#_Toc125966874)

[17. Compensation to Participants 11](#_Toc125966875)

[18. Data Analysis, Management and Confidentiality 11](#_Toc125966876)

[19. Provisions to Monitor the Data to Ensure the Safety of Participants 11](#_Toc125966877)

[20. Provisions to Protect the Privacy Interest of Participants 12](#_Toc125966878)

[21. Economic Burden to Participants 13](#_Toc125966879)

[22. Informed Consent 13](#_Toc125966880)

[23. HIPAA 15](#_Toc125966881)

[24. Setting 16](#_Toc125966882)

[25. Resources Available 16](#_Toc125966883)

[26. Multi-Site or Collaborative Research 17](#_Toc125966884)

[27. References 18](#_Toc125966885)

[28. Protocol Checklist 18](#_Toc125966886)

# Study Summary

|  |  |
| --- | --- |
| **Study Title** |  |
| **Study Design** |  |
| **Primary Objective** |  |
| **Secondary Objective(s)** |  |
| **Research Intervention(s)/Interactions** |  |
| **Study Population** |  |
| **Sample Size** |  |
| **Study Duration for individual participants** |  |
| **Study Specific Abbreviations/ Definitions** |  |
| **Funding Source (if any)** |  |

# Objectives

Describe the purpose, specific aims, or objectives and state the hypotheses to be tested.

The following must be addressed when study involves developing/evaluating an algorithm/clinical decision tool/artificial intelligence/machine learning tool(s)):

* Whether data will or may be submitted to FDA
* Whether there is a plan to test the model clinically (i.e., providing any output to healthcare provider(s) or patients at this stage) in the current submission. If there are no plans to test the model clinically in this protocol, note that a new IRB submission will be required if it will be tested clinically in the future.
* Whether the Algorithm/Product/Software is intended to become proprietary, and can/will it be commercialized outside of Emory?

(Add your text)

# Background

* Describe the relevant prior experience and gaps in current knowledge. Describe any relevant preliminary data. Provide the scientific or scholarly background for, rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge. Describe any relevant preliminary data or knowledge to be built upon in this study. Examples of issues to address are cultural expectations, political conditions, economic conditions, disease prevalence/incidence, environmental factors.
* Provide the scientific or scholarly background for, rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge.
* Include any other non-research rationale for the work, if this study is a mix of non-research and research

(Add your text)

# Study Endpoints

Describe the primary and secondary study endpoints. Describe any primary or secondary safety endpoints.

(Add your text)

# Study Intervention/Design

Describe the study intervention that is being evaluated, and/or the nature of interactions proposed.

(Add your text)

# Procedures Involved

Describe and explain the study design in more detail.

Provide a description of all research procedures being performed and when they are performed, including procedures being performed to monitor participants for safety or minimize risks.

Describe:

* Procedures performed to lessen the probability or magnitude of risks.
* The source records that will be used to collect data about participants. (Attach all surveys, scripts, and data collection forms in Smartform on “Study-Related Documents” page under “Other Attachments.” If unable to attach data collection instruments due to copyright requirements, include description of the instrument in the protocol document
* What data, specifically, will be collected during the study and how that data will be obtained.
* If there are plans for long-term follow-up (once all research related procedures are complete), what data will be collected during this period.
* Detail whether any of the following are brought to an Emory research laboratory for further experimentation: microorganisms or infectious materials; nanomaterials; genetically modified primary cells or cell lines; genetically modified live or live-attenuated microbes (e.g., bacteria, fungi, virus, etc.); arthropods; plant products; toxins; environmental samples; human cells, cell lines, stool samples, or other human source materials; and human blood, blood products or tissue. (Note: If yes, then EHSO Biosafety ancillary review is required.)
* If audio/video-recordings will be generated, describe processes for transcribing audio/video recordings. Will audio-recordings be destroyed after transcription? If so, how long after transcription? If not, how will they be kept secure? If video-recordings will be used beyond the current research procedures for educational/presentation purposes.
* Does the research design require subjects to be deceived?
* Describe and justify need for deception.
* Describe plan to debrief participants after study participation is completed.
* Will the subjects be exposed to any stress?
* Describe and justify need for stress.

(Add your text)

# Data Specimen Banking

* If data or specimens will be banked for future use, describe where the specimens will be stored, how long they will be stored, how the specimens will be accessed, and who will have access to the specimens. (may require a separate repository-specific IRB submission). The VA Data Repository SOP is required if the study is creating a data repository at the Atlanta VA
* List the data to be stored or associated with each specimen.
* Describe the procedures to release data or specimens, including the process to request a release, approvals required for release, who can obtain data or specimens, and the data to be provided with specimens.

(Add your text)

# Sharing of Results with Participants

Describe whether results (study results or individual subject results, such as results of investigational diagnostic tests, genetic tests, or incidental findings) will be shared with participants or others (e.g., the subject’s primary care physicians) and if so, describe how the results will be shared.

(Add your text)

# Study Timelines

Describe the duration of an individual subject’s participation in the study, the duration anticipated to enroll all study participants and the approximate total duration of overall study

(Add your text)

# Inclusion and Exclusion Criteria

Inclusion Criteria: Describe generally the individuals that will be included in your study.

Describe any subject populations that will be specifically targeted

Exclusion Criteria: Describe specifically any subject populations that will be excluded from your sample.

# Population

Indicate specifically whether you will include or exclude any of the following special populations: (You may not include members of these populations as participants in your research unless you include them in the description of your subject population.)

* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
* Cognitively impaired or Individuals with Impaired Decision-Making Capacity
* Individuals who are not able to clearly understand English(If you indicated you will exclude, please provide reasoning.)

Community Participation (if applicable)

For studies aimed at addressing issues that affect a certain community or group, how, if at all, will this study involve people from the target community in the design of the study? Conduct of the study? How will the results of the research be shared with the participants and/or the target community(ies)?

If your research questions involve race and/or ethnicity, please clarify the following:

(1) Describe the definition you are using for “Race” and/or “Ethnicity” in this study (examples here (link to [JAMA](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F2776936&data=04%7C01%7Crebecca.rousselle%40emory.edu%7C98fd1abfb9004c48e8fb08d9a583cf9f%7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%7C637722807820672228%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=lEegCWT0%2Byid8HZ%2FBk%2FuP1rTaABQlAiGQW%2FIyoKBawU%3D&reserved=0), [JHM](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.journalofhospitalmedicine.com%2Fjhospmed%2Farticle%2F235223%2Fhospital-medicine%2Fnew-author-guidelines-addressing-race-and-racism-journal&data=04%7C01%7Crebecca.rousselle%40emory.edu%7C98fd1abfb9004c48e8fb08d9a583cf9f%7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%7C637722807820682221%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=aCTdniEe5lj%2F8cHWWhNKweykajcbqk7kUYjxZi4wf2s%3D&reserved=0), [AHA](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ahajournals.org%2Fdisparities-research-guidelines&data=04%7C01%7Crebecca.rousselle%40emory.edu%7C98fd1abfb9004c48e8fb08d9a583cf9f%7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%7C637722807820682221%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=SFwpaswIRrcefX0z3eE0vj5GUo4shR60EIiTiQUCl90%3D&reserved=0), and [Health Affairs](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.healthaffairs.org%2Fdo%2F10.1377%2Fhblog20200630.939347%2Ffull%2F&data=04%7C01%7Crebecca.rousselle%40emory.edu%7C98fd1abfb9004c48e8fb08d9a583cf9f%7Ce004fb9cb0a4424fbcd0322606d5df38%7C0%7C0%7C637722807820692211%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=UIPb8XoHu6Xj1hKNSfb2XBBzcw3BnaExQvOKCooG06Q%3D&reserved=0) guidance). (2) State whether you are using racial and ethnic classification of patients for descriptive statistics or within an explanatory model (as a covariate). (3) If you are using race and/or ethnicity as a variable to explain differences between patients (as a covariate), please describe the proposed mechanism of action (what is race being used as a proxy for?).

If the research involves individuals who are vulnerable to coercion or undue influence, describe additional safeguards included to protect their rights and welfare.

If the research involves pregnant women, human fetuses, or neonates of uncertain viability or non-viable neonates review the “[Pregnant Women, Fetuses, and Neonates Checklist”](http://irb.emory.edu/documents/Emory%20Subpart%20B%20Worksheet.doc) to ensure that you have provided enough information.

If the research involves prisoners, review the “[Prisoner Subjects Checklist”](http://irb.emory.edu/documents/Emory%20Subpart%20C%20Worksheet.doc) to ensure that you have provided enough information.

If the research involves persons who have not attained the legal age for consent to treatments or procedures involved in the research (“children”), review the “[Minor/Children Subjects Checklist](http://irb.emory.edu/documents/Emory%20Subpart%20D%20Worksheet.doc)” to ensure that you have provided enough information.

If the research involves cognitively impaired adults, review the “[Cognitively Impaired Checklist”](http://irb.emory.edu/documents/CHECKLIST-Cognitively_Impaired_Adults.docx) to ensure that you have provided enough information.

(Add your text)

# Local Number of Participants

Indicate the total number of participants to be accrued locally.

If applicable, distinguish between the number of participants who are expected to be enrolled and screened, and the number of participants needed to complete the research procedures (i.e., numbers of participants excluding screen failures.)

Provide your projected enrolling goals, including the percentage of participants according to sex and race.

(Add your text)

# Recruitment Methods

* Describe when, where, and how potential participants will be recruited, who will make initial contact and how.
* Describe the source of participants.
* Describe the methods that will be used to identify potential participants.
* Describe materials that will be used to recruit participants. (Attach copies of these documents in Smartform on the “Study-Related Documents” page under “Recruitment material templates.” with the application. For advertisements, attach the final copy of printed advertisements. When advertisements are taped for broadcast, attach the final audio/videotape. You may submit the wording of the advertisement before taping to preclude re-taping because of inappropriate wording, provided the IRB reviews the final audio/videotape.)
* How will eligibility be determined? Provide a detailed description of any eligibility screening done before enrolling the subject (including whether any identifiers will be recorded – note that IP address is an identifier)
* If using contests or raffles as incentive, you must offer entry to all potential participants, not just those who enroll in the study/complete study-related procedures, per Georgia State Law.
* If recruiting online, describe how potential participants would be directed to your recruitment information and study description.
* All research recruitment through social media needs to [follow this guidance](http://irb.emory.edu/documents/Guidance-Using_Social_Media_Recruit_participants.pdf), which does not allow the use of personal social media accounts for some recruitment activities.

(Add your text)

# Withdrawal of Participants

Describe anticipated circumstances under which participants will be withdrawn from the research without their consent.

Describe procedures that will be followed when participants withdraw from the research, including partial withdrawal from procedures with continued data collection.

(Add your text)

# Risk to Participants

List the reasonably foreseeable risks, discomforts, hazards, or inconveniences to the participants related the participants’ participation in the research.

Include as may be useful for the IRB’s consideration, a description of the probability, magnitude, duration, and reversibility of the risks.

Consider physical, psychological, social, legal, and economic risks. Include risks of loss of privacy or breach of confidentiality.

If applicable, indicate which procedures may have risks to the participants that are currently unforeseeable.

If applicable, indicate which procedures may have risks to an embryo or fetus should the subject be or become pregnant.

If applicable, describe risks to others who are not participants.

Do not state that there are no risks. (Add your text)

# Potential Benefits to Participants

Describe the potential benefits that individual participants may experience

Indicate if there is no direct benefit. Do not include benefits to society or others.

Describe areas of knowledge that would be strengthened.

(Add your text)

# Compensation to Participants

Describe if/how subjects will be compensated for participation in this study. Indicate what method compensation will be delivered (e.g. cash, gift card, school credit). Describe the amount and timing of any payments to participants. How much? What kind? Is tax information required? (if so, must be reflected in the informed consent form). Will payments be pro-rated if a participant withdraws early?

(Add your text)

# Data Analysis, Management and Confidentiality

Describe the data analysis plan, including any statistical procedures or power analysis.

Describe the steps that will be taken to secure the data (e.g., training, authorization of access, password protection, encryption, physical controls, certificates of confidentiality, and separation of identifiers and data) during storage, use, and transmission.

Describe any procedures that will be used for quality control of collected data.

Describe how data or specimens will be handled study-wide:

* What information will be included in that data or associated with the specimens?
* Where and how data or specimens will be stored?
* How long the data or specimens will be stored?
* Who will have access to the data or specimens?
* Will any data be shared with an external entity or non-Emory collaborator? If so, clarify what identifiers will be included with the data.
* Will any identifiable data be shared via a platform/software/eConsent/app? If not a [vetted option](https://it.emory.edu/security/protecting-data/software_for_research.html), please note [Emory OIT security review](https://emory.service-now.com/sp?id=kb_article&sys_id=e5c2cd88f5cdf1c055c77bd8604896c2) may be required.
* Who is responsible for receipt or transmission of the data or specimens?
* How data or specimens will be transported?

(Add your text)

# Provisions to Monitor the Data to Ensure the Safety of Participants

**This section is required when research involves more than Minimal Risk to participants.**

Ensure that you review our [Data and Safety Monitoring plan guidance](http://www.irb.emory.edu/documents/DSMP_requirements.pdf) for specific details about this section, and examples of what the IRB will be requiring according to the level of risk.

If a DSMB is needed, please describe the composition of the board (if not already detailed in the protocol). [Review this guidance](http://www.irb.emory.edu/documents/DSMB-Guidance.pdf) for more information. If the sponsor protocol does not contain all required information, please in this section.

Describe the plan to periodically monitor the data at the site level, and if you have international sites.

Description of the plan for notifying the IRB of reportable events; whether the sponsor requires reporting above and beyond the Emory IRB reporting requirements, and if so, a description of the requirements and plan for meeting them.

Please address the specific details below. If deemed not applicable, please provide rationale:

Subject safety:

* Specific subject safety parameters
* Frequency of subject safety observations
* Individual responsible for safety monitoring
* Subject stopping rules – under what conditions will a subject be removed from study participation and who will make the decision?
* Study stopping rules - under what conditions will the study be modified or stopped and who will make the decision?
* Reporting mechanisms (i.e. Deviations, adverse events, UPs)

Data Integrity:

* Specific data elements to be reviewed
* Frequency of monitoring data, points in time, or after a specific number of participants
* Individual responsible for data monitoring

(Add your text)

# Provisions to Protect the Privacy Interest of Participants

Describe the steps that will be taken to protect participants’ privacy interests. “Privacy interest” refers to a person’s desire to place limits on whom they interact or whom they provide personal information.

Describe what steps you will take to make the participants feel at ease with the research situation in terms of the questions being asked and the procedures being performed. “At ease” does not refer to physical discomfort, but the sense of intrusiveness a participant might experience in response to questions, examinations, and procedures.

Indicate how the research team is permitted to access any sources of information about the participants.

What are your plans to establish and maintain confidentiality of participants’ identifiable data?

Describe any linkages from study data to identifiers.

* Will you destroy identifiers (includes audio/video recording files)? If so, at what stage?
* Will all results of research tests be placed in the participant’s Emory medical record?

(Add your text)

# Economic Burden to Participants

Describe any costs that participants may be responsible for because of participation in the research.

(Add your text)

# Informed Consent

Indicate whether you will be obtaining informed consent and if so, describe:

* Where will the consent process take place?
* Will there be any waiting period between informing the prospective participant and obtaining the consent?
* Will there be a process to ensure ongoing consent?
* Please describe:
  + The role of the individuals listed in the application as being involved in the consent process.
  + The time that will be devoted to the consent discussion.
  + Steps that will be taken to minimize the possibility of coercion or undue influence.
  + Steps that will be taken to ensure the participants’ understanding.

Note: If you are planning to obtain consent via electronic signature, please review [this document](http://www.irb.emory.edu/documents/guidance-eICF_use.pdf). Additional guidance on consent documentation and process can be found on our website, under the [consent toolkit](http://www.irb.emory.edu/forms/consent_toolkit/guidance.html).

(Add your text)

**Non-English-Speaking Participants**

* Indicate what language(s) other than English are understood by prospective participants or representatives.
* If participants who do not speak English will be enrolled, describe the process to ensure that the oral and written information provided to those participants will be in that language. Indicate the language that will be used by those obtaining consent.
* If you checked N/A, please provide reasoning of why subjects with limited English proficiency are excluded.

Note: if you stated that subjects with LEP will be enrolled, you are approved for the use of the Emory IRB short forms. Please read the guidance about the use of short forms [here](https://irb.emory.edu/forms/consent/shortforms.html).

(Add your text)

Participants who are not yet adults (infants, children, teenagers)

* Describe the criteria that will be used to determine whether a prospective participant has not attained the legal age for consent to treatments or procedures involved in the research under the applicable law of the jurisdiction in which the research will be conducted. (E.g., individuals under the age of 18 years.)
* For research conducted in Georgia, review “Emory IRB Policies and Procedures: 53 RESEARCH INVOLVING CHILDREN – ADDITIONAL PROTECTIONS” and “46 LEGALLY AUTHORIZED REPRESENTATIVES AND SURROGATE CONSENT” to be aware of which individuals in the state meet the definition of “children.”
* For research conducted outside of Georgia, provide information that describes which persons have not attained the legal age for consent to treatments or procedures involved in the research, under the applicable law of the jurisdiction in which research will be conducted. Please reference Emory IRB Policies and Procedures chapters 53 RESEARCH INVOLVING CHILDREN – ADDITIONAL PROTECTIONS and 46 LEGALLY AUTHORIZED REPRESENTATIVES AND SURROGATE CONSENT.

Describe whether parental permission will be obtained from:

* Both parents unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child.
* One parent even if the other parent is alive, known, competent, reasonably available, and shares legal responsibility for the care and custody of the child.

Describe whether permission will be obtained from individuals other than parents, and if so, who will be allowed to provide permission. Describe the process used to determine these individuals’ authority to consent to each child’s general medical care.

Indicate whether assent will be obtained from all, some, or none of the children. If assent will be obtained from some children, indicate which children will be required to assent.

When assent of children is obtained describe whether and how it will be documented.

(Add your text)

**Cognitively Impaired Adults**

Describe the process to determine whether an individual is capable of consent. The IRB allows the person obtaining assent to document assent on the consent document and does not routinely require assent documents and does not routinely require children to sign assent documents.

(Add your text)

**Adults Unable to Consent**

* List the individuals from whom permission will be obtained in the order of priority. (E.g., durable power of attorney for health care, a court-appointed guardian for health care decisions, spouse, and adult child.)
* For research conducted in the state, review Chapter 46 LEGALLY AUTHORIZED REPRESENTATIVES AND SURROGATE CONSENT to be aware of which individuals in the state meet the definition of “legally authorized representative.”
* For research conducted outside of the state, provide information that describes which individuals are authorized under applicable law to consent on behalf of a prospective subject to their participation in the procedure(s) involved in this research.

Describe the process for the assent of the participants. Indicate whether:

* Assent will be required of all, some, or none of the participants. If some, indicated, which participants will be required to provide assent and which will not.
* If assent will not be obtained from some or all participants, an explanation of why not.
* Describe whether the assent of the participants will be documented and the process to document assent. The IRB allows the person obtaining assent to document assent on the consent document and does not routinely require assent documents and does not routinely require participants to sign assent documents.

(Add your text)

**Waiver or Alteration of Consent Process (consent will not be obtained, required information will not be disclosed, or the research involves deception)**

* Review the [Emory IRB waiver document](http://www.irb.emory.edu/documents/Combined_Waiver_Consent_HIPAA_Elements.docx) to ensure you have provided sufficient information for the IRB to make these determinations.
* If the research involves a waiver of the consent process for planned emergency research, please review the Emory P&Ps, Chapter 48, WAIVERS OF, AND EXCEPTIONS FROM, INFORMED CONSENT FOR PLANNED EMERGENCY RESEARCH to ensure you have provided sufficient information for the IRB to make these determinations.

(Add your text)

# HIPAA

If you are recording identifiers from the medical record from subjects who are still living, and it is not practicable to obtain their HIPAA authorization for your study, you will need to request a HIPAA waiver.

Please address how your request meets the following criteria:

* The use or disclosure of PHI involves no more than a minimal risk to the privacy of individuals, based on, at least, the presence of the following elements:
* An adequate plan to protect the identifiers from improper use and disclosure;
* An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers, or such retention is otherwise required by law; and
* Adequate written assurances that the PHI will not be reused or disclosed to any other person or entity, except as required by law, or for authorized oversight of the research study, or for other research for which the use or disclosure of PHI would be permitted by this subpart.
* The research could not practicably be conducted without the waiver or alteration.
* The research could not practicably be conducted without access to and use of the protected health information.

(Add your text)

# Setting

Describe the sites or locations where your research team will conduct the research.

* Identify where your research team will identify and recruit potential participants.
* Identify where research procedures will be performed.
* Describe the composition and involvement of any community advisory board.
* For research conducted outside of the organization and its affiliates describe:
  + Site-specific regulations or customs affecting the research for research outside the organization.
  + Local scientific and ethical review structure outside the organization

(Add your text)

# Resources Available

Describe the resources available to conduct the research: For example, as appropriate:

* Justify the feasibility of recruiting the required number of suitable participants within the agreed recruitment period. For example, how many potential participants do you have access to? What percentage of those potential participants do you need to recruit?
* Describe the time that you will devote to conducting and completing the research.
* Describe your facilities.
* Describe the availability of medical or psychological resources that participants might need as a result of anticipated consequences of the human research.
* Describe your process to ensure that all persons assisting with the research are adequately informed about the protocol, the research procedures, and their duties and functions.

(Add your text)

# Multi-Site or Collaborative Research

List external collaborators on the first page of this protocol including whether external collaborators are seeking IRB approval from Emory IRB or their own IRBs. If there are any external collaborators seeking approval from Emory IRB, please reach out to the reliance team at [irb.reliance@emory.edu](mailto:irb.reliance@emory.edu). Please see our [collaborative page](https://www.irb.emory.edu/guidance/research-types/collaborative.html) for more information.

Study -Wide Number of Participants

If this is a multicenter study, indicate the total number of participants to be accrued across all sites.

Study-Wide Recruitment Methods

* If this is a multicenter study and participants will be recruited by methods, not under the control of the local site (e.g., call centers, national advertisements) describe those methods. Local recruitment methods are described later in the protocol.
* Describe when, where, and how potential participants will be recruited.
* Describe the methods that will be used to identify potential participants.
* Describe materials that will be used to recruit participants. (Attach copies of these documents with the application. For advertisements, attach the final copy of printed advertisements. When advertisements are taped for broadcast, attach the final audio/videotape. You may submit the wording of the advertisement before taping to preclude re-taping because of inappropriate wording, provided the IRB reviews the final audio/videotape.)
* Describe the processes to ensure communication among sites. All sites have the most current version of the protocol, consent document, and HIPAA authorization. All required approvals (initial, continuing review, and modifications) have been obtained at each site (including approval by the site’s IRB of record).
* All modifications have been communicated to sites and approved (including approval by the site’s IRB of record) before the modification is implemented.
* All engaged participating sites will safeguard data, including the secure transmission of data, as required by local information security policies.
* All local site investigators conduct the study following applicable federal regulations and local laws.
* All non-compliance with the study protocol or applicable requirements will be reported following local policy

Describe the method for communicating to engaged participating sites:

* Problems (inclusive of reportable events).
* Interim results.
* The closure of a study

If this is a multicenter study where you are a participating site/investigator, describe the local procedures for maintenance of confidentiality.

* Where and how data or specimens will be stored locally?
* How long the data or specimens will be stored locally?
* Who will have access to the data or specimens locally?
* Who is responsible for receipt or transmission of the data or specimens locally?
* How data and specimens will be transported locally?

(Add your text)

# References

Add references.

(Add your text)

# Protocol Checklist

**Please note that protocol sections with an asterisk (\*)should always be included in the protocol; if the section does not have an asterisk, and you have not included the section in the protocol, the IRB will consider it your attestation that the section does not apply to your study.**

|  |  |
| --- | --- |
| **Protocol Section** | **Added to the protocol?** |
| **External Collaborators**- if applicable, add each external collaborator information and indicate whether that institution’s IRB will review (or has already reviewed) that individual’s engagement in human participants research activities) | **Yes** |
| **Funding Source*\****: Include the information for the funding entity for this study. Please explain if this study is covered by a sub-award or other pertinent information. Say “department” if you do not have any other funding. | **Yes** |
| **Objectives*\**:** Describe the purpose, specific aims, or objectives and state the hypotheses to be tested | **Yes** |
| **Background*\**:** Describe the relevant prior experience and gaps in current knowledge. Describe any relevant preliminary data. Provide the scientific or scholarly background for, the rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge. Describe any relevant preliminary data or knowledge to be built upon in this study. Examples of issues to address are cultural expectations, political conditions, economic conditions, disease prevalence/incidence, environmental factors.  Provide the scientific or scholarly background for, the rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge.  Include any other non-research rationale for the work, if this study is a mix of non-research and research | **Yes** |
| **Study Endpoints:** Sample: provide some information about the data set that the research team will be analyzing. | **Yes** |
| **Study Intervention/Design\*:** Describe the study intervention that is being evaluated, and/or the nature of interactions proposed. | **Yes** |
| **Procedures involved\***: Describe and explain the study design in more detail.  Describe all research procedures being performed and when they are performed, including procedures being performed to monitor participants for safety or minimize risks. Procedures performed to lessen the probability or magnitude of risks. | **Yes** |
| **Procedures-Source Records\*:** The source records that will be used to collect data about participants. (Attach all surveys, scripts, and data collection forms in the smartform on the “Study-Related Documents” page under “Other Attachments.” If unable to attach data collection instruments due to copyright requirements, include a description of the instrument in the protocol document | **Yes** |
| **Procedures-Data collection\*:** What data, specifically, will be collected during the study, and how that data will be obtained. If audio/video-recordings will be generated, describe processes for transcribing audio/video recordings. Will audio-recordings be destroyed after transcription? If so, how long after transcription? If not, how will they be kept secure? If video-recordings will be used beyond the current research procedures for educational/presentation purposes. | **Yes** |
| **Procedures- Long Term Follow Up\*:** If there are plans for long-term follow-up (once all research-related procedures are complete), what data will be collected during this period. | **Yes** |
| **Procedures-Deception:** Does the research design require subjects to be deceived? Describe and justify the need for deception. Describe the plan to debrief participants after study participation is completed. Will the subjects be exposed to any stress? Describe and justify the need for stress. | **Yes** |
| **Data and Specimen Banking:** If data or specimens will be banked for future use, describe where the data or specimens will be stored, how long they will be stored, how the data or specimens will be accessed, and who will have access to the data or specimens. List the data to be stored or associated with each specimen. Describe the procedures to release data or specimens, including the process to request a release, approvals required for release, who can obtain data or specimens, and the data to be provided with specimens. | **Yes** |
| **Sharing of Results with Participants\*:** Describe whether results (study results or individual subject results, such as results of investigational diagnostic tests, genetic tests, or incidental findings) will be shared with participants or others (e.g., the subject’s primary care physicians) and if so, describe how the results will be shared. | **Yes** |
| **Study timelines\*:** Describe the duration of an individual subject’s participation in the study, the duration anticipated to enroll all study participants, and the approximate total duration of the overall study | **Yes** |
| **Population and Inclusion/Exclusion Criteria\*:** Describe how individuals will be screened for eligibility; the criteria that define who will be included or excluded in your final study sample; and indicate specifically whether you will include or exclude each of the following special populations:   * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners   Note: you cannot exclude people with limited English proficiency unless you can demonstrate the scientific need for such exclusion.  Community Participation: For studies aimed at addressing issues that affect a certain community or group: How, if at all, will this study involve people from the target community in the design of the study? Conduct of the study? How will the results of the research be shared with the participants and/or the target community/ies? | **Yes** |
| **Research with pregnant women, fetuses, or neonates:** review [this checklist](http://irb.emory.edu/documents/Emory%20Subpart%20B%20Worksheet.doc) to verify you have provided enough information to ensure the safety and well-being of this population. | **Yes** |
| **Research with neonates of uncertain viability:** review [this checklist](http://irb.emory.edu/documents/Emory%20Subpart%20B%20Worksheet.doc) to verify you have provided enough information to ensure the safety and well-being of this population. | **Yes** |
| **Research involving prisoners:** review [this checklist](http://irb.emory.edu/documents/Emory%20Subpart%20C%20Worksheet.doc) to verify you have provided enough information to ensure the safety and well-being of this population. | **Yes** |
| **Research involving children:** review [this checklist](http://irb.emory.edu/documents/Emory%20Subpart%20D%20Worksheet.doc) to verify you have provided enough information to ensure the safety and well-being of this population. | **Yes** |
| **Research involving cognitively impaired adults:** review [this checklist](http://irb.emory.edu/documents/CHECKLIST-Cognitively_Impaired_Adults.docx) to verify you have provided enough information to ensure the safety and well-being of this population. | **Yes** |
| **Research involving economically or educationally disadvantaged persons:** describe the additional safeguards that have been included in the study to protect the rights and welfare of these subjects | **Yes** |
| **Local Number of Participants\*:** Indicate the total number of participants to be accrued locally. If applicable, distinguish between the number of participants who are expected to be enrolled and screened, and the number of participants needed to complete the research procedures (i.e., numbers of participants excluding screen failures.)  Provide your projected enrolling goals, including the percentage of participants according to sex and race. | **Yes** |
| **Recruitment Methods\*:** Describe when, where, and how potential participants will be recruited, who will make initial contact and how, and if physicians or staff refer participants. Describe the source of participants. Describe the methods that will be used to identify potential participants. Describe materials that will be used to recruit participants. (Attach copies of these documents in Smartform on the “Study-Related Documents” page under “Recruitment material templates.” with the application. For advertisements, attach the final copy of printed advertisements. When advertisements are taped for broadcast, attach the final audio/videotape. You may submit the wording of the advertisement before taping to preclude re-taping because of inappropriate wording, provided the IRB reviews the final audio/videotape.) How will eligibility be determined? Provide a detailed description of any eligibility screening done before enrolling the subject (including whether any identifiers will be recorded – note that IP address is an identifier). If recruiting online, describe how potential participants would be directed to your recruitment information and study description.  If using contests or raffles as an incentive, you must offer entry to all potential participants, not just those who enroll in the study/complete study-related procedures, per Georgia State Law.  If recruiting online, describe how potential participants would be directed to your recruitment information and study description.  All research recruitment through social media needs to [follow this guidance](http://irb.emory.edu/documents/Guidance-Using_Social_Media_Recruit_participants.pdf), which does not allow the use of personal social media accounts for some recruitment activities | **Yes** |
| **Withdrawal of Participants\*:** Describe anticipated circumstances under which participants will be withdrawn from the research without their consent. Describe procedures that will be followed when participants withdraw from the research, including partial withdrawal from procedures with continued data collection. | **Yes** |
| **Risk to Participants\*:** List the reasonably foreseeable risks, discomforts, hazards, or inconveniences to the participants related to the participant's participation in the research. Include as may be useful for the IRB’s consideration, a description of the probability, magnitude, duration, and reversibility of the risks. Consider physical, psychological, social, legal, and economic risks. Include risks of loss of privacy or breach of confidentiality.  If applicable, indicate which procedures may have risks to the participants that are currently unforeseeable.  If applicable, indicate which procedures may have risks to an embryo or fetus should the subject be or become pregnant.  If applicable, describe risks to others who are not participants.  Do not state that there are no risks. | **Yes** |
| **Potential Benefits to Participants\*:** Describe the potential benefits that individual participants may experience  Indicate if there is no direct benefit. Do not include benefits to society or others.  Describe areas of knowledge that would be strengthened.  Compensation should NOT be stated as a benefit. | **Yes** |
| **Compensation to Participants\*:** Describe if/how subjects will be compensated for participation in this study. Indicate what method compensation will be delivered (e.g. cash, gift card, school credit).  Describe the amount and timing of any payments to participants. How much? What kind? Is tax information required? (if so, must be reflected in the informed consent form). Will payments be pro-rated if a participant withdraws early? | **Yes** |
| **Data Analysis, Management and Confidentiality\*:** Describe the data analysis plan, including any statistical procedures or power analysis. Describe the steps that will be taken to secure the data (e.g., training, authorization of access, password protection, encryption, physical controls, certificates of confidentiality, and separation of identifiers and data) during storage, use, and transmission. Describe any procedures that will be used for the quality control of collected data. | **Yes** |
| **Describe how data or specimens will be handled study-wide\*:** What information will be included in that data or associated with the specimens?   * Where and how data or specimens will be stored? * How long the data or specimens will be stored? * Who will have access to the data or specimens? * Who is responsible for receipt or transmission of the data or specimens? * How data or specimens will be transported? | **Yes** |
| **Data Monitoring and Participants Safety**  **(if this study is no more than minimal risk, this section is not required)**   * Ensure that you review our [Data and Safety Monitoring plan guidance](http://irb.emory.edu/documents/DSMP_requirements_ver_2-2-2021.pdf) for specific details about this section, and examples of what the IRB will be requiring according to the level of risk. * If a DSMB is needed, please describe the composition of the board (if not already detailed in the protocol). [Review this guidance](http://irb.emory.edu/documents/DSMB-DSMPGuidance.pdf) for more information. If the sponsor protocol does not contain all required information, please in this section. * Describe the plan to periodically monitor the data at the site level, and if you have international sites. * Description of the plan for notifying the IRB of reportable events; whether the sponsor requires reporting above and beyond the Emory IRB reporting requirements, and if so, a description of the requirements and plan for meeting them. * Please address the specific details below. If deemed not applicable, please provide rationale: * Subject safety:   + Specific subject safety parameters   + Frequency of subject safety observations   + Individual responsible for safety monitoring   + Subject stopping rules – under what conditions will a subject be removed from study participation and who will make the decision?   + Study stopping rules - under what conditions will the study be modified or stopped and who will make the decision?   + Reporting mechanisms (i.e. Deviations, adverse events, UPs) * Data Integrity:   + Specific data elements to be reviewed   + Frequency of monitoring data, points in time, or after a specific number of participants   + Individual responsible for data monitoring | **Yes** |
| **Provisions to Protect the Privacy Interests of Participants\*:**   * Describe the steps that will be taken to protect participants’ privacy interests. “Privacy interest” refers to a person’s desire to place limits on whom they interact with or whom they provide personal information. * Describe what steps you will take to make the participants feel at ease with the research situation in terms of the questions being asked and the procedures being performed. “At ease” does not refer to physical discomfort, but the sense of intrusiveness a participant might experience in response to questions, examinations, and procedures. * Indicate how the research team is permitted to access any sources of information about the participants. | **Yes** |
| **Economic Burden to Participants\*:** Describe any costs that participants may be responsible for because of participation in the research. | **Yes** |
| **Informed Consent\*:** Describe where the consent process will take place, any waiting period available between informing the prospective subject and obtaining the consent; and the process to ensure ongoing consent.  Describe the role of the individuals listed in the application as being involved in the consent process; the time that will be devoted to the consent discussion; steps that will be taken to minimize the possibility of coercion or undue influence; and steps that will be taken to ensure the participants’ understanding.  Note: If you are planning to obtain consent via electronic signature, please review [this document](http://www.irb.emory.edu/documents/guidance-eICF_use.pdf). Additional guidance on consent documentation and process can be found on our website, under the [consent toolkit](http://www.irb.emory.edu/forms/consent_toolkit/guidance.html). | **Yes** |
| **Consent Process-Non-English-Speaking Participants\*:**  Indicate what language(s) other than English are understood by prospective participants or representatives.  If participants who do not speak English will be enrolled, describe the process to ensure that the oral and written information provided to those participants will be in that language. Indicate the language that will be used by those obtaining consent.  If you checked N/A, please provide reasoning of why subjects with limited English proficiency are excluded.  **Note**: if you stated that subjects with LEP will be enrolled, you are approved for the use of the Emory IRB short forms. Please read the guidance about the use of short forms [here](https://irb.emory.edu/forms/consent/shortforms.html). | **Yes** |
| **Consent Process-Children:** After determining if the subject is a child per GA law (or if enrolled outside GA, per state/country law), please describe whether parental permission will be obtained from:   * Both parents unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child. * One parent even if the other parent is alive, known, competent, reasonably available, and shares legal responsibility for the care and custody of the child.   Describe whether permission will be obtained from individuals other than parents, and if so, who will be allowed to provide permission. Describe the process used to determine these individuals’ authority to consent to each child’s general medical care.  When assent of children is obtained describe whether and how it will be documented per Emory Policies and Procedures | **Yes** |
| **Consent Process-Cognitively Impaired Adults:** describe the process to determine whether an individual is capable of consent. The IRB allows the person obtaining assent to document assent on the consent document and does not routinely require assent documents and does not routinely require children to sign assent documents. | **Yes** |
| **Consent Process-Adults Unable to Consent:**  List the individuals from whom permission will be obtained in the order of priority. (E.g., durable power of attorney for health care, a court-appointed guardian for health care decisions, spouse, and adult child.)  For research conducted in the state, review “46 LEGALLY AUTHORIZED REPRESENTATIVES AND SURROGATE CONSENT” to be aware of which individuals in the state meet the definition of “legally authorized representative.”  For research conducted outside of the state, provide information that describes which individuals are authorized under applicable law to consent on behalf of a prospective subject to their participation in the procedure(s) involved in this research.  Describe the process for the assent of the participants. Indicate whether:   * Assent will be required of all, some, or none of the participants. If some, indicated, which participants will be required to assent and which will not. * If assent will not be obtained from some or all participants, an explanation of why not.   Describe whether the assent of the participants will be documented and the process to document assent. The IRB allows the person obtaining assent to document assent on the consent document and does not routinely require assent documents and does not routinely require participants to sign assent documents | **Yes** |
| **Waiver or Alteration of Consent and HIPAA authorization (consent will not be obtained, required information will not be disclosed, or the research involves deception)**  Review the [Emory IRB waiver document](http://www.irb.emory.edu/documents/Combined_Waiver_Consent_HIPAA_Elements.docx) to ensure you have provided sufficient information for the IRB to make these determinations.  If the research involves a waiver of the consent process for planned emergency research, please review the Emory P&Ps, Chapter 48, WAIVERS OF, AND EXCEPTIONS FROM, INFORMED CONSENT FOR PLANNED EMERGENCY RESEARCH to ensure you have provided sufficient information for the IRB to make these determinations. | **Yes** |
| **Setting\*:** Describe the sites or locations where your research team will conduct the research including where the subject will be identified and recruited, where the research procedures will be performed, and if you will involve a community advisory board. For research conducted outside the organization and its affiliates describe the site-specific regulations or customs affecting the research outside the organization and the local scientific and ethical review structure outside the organization. | **Yes** |
| **Resources Available\*:** Describe the resources available to conduct the research such us the feasibility of recruiting the required number of suitable participants within the agreed recruitment period; describe the time that you will devote to conducting and completing the research; describe the availability of medical or psychological resources that participants might need as a result of an anticipated consequences of the human research; describe your process to ensure that all persons assisting with the research are adequately informed about the protocol, the research procedures, and their duties and functions. | **Yes** |
| **Multi-Site Research when Emory is the Lead Site**  Study -Wide Number of Participants: indicate the total number of participants to be accrued across all sites.  Study-Wide Recruitment Methods: If this is a multicenter study and participants will be recruited by methods not under the control of the local site (e.g., call centers, national advertisements) describe those methods.  Describe when, where, and how potential participants will be recruited.  Describe the methods that will be used to identify potential participants.  Describe materials that will be used to recruit participants.  Describe the processes to ensure communication among sites. See “WORKSHEET: Communication and Responsibilities (HRP-830).” All sites have the most current version of the protocol, consent document, and HIPAA authorization.  All required approvals (initial, continuing review and modifications) have been obtained at each site (including approval by the site’s IRB of record).  All modifications have been communicated to sites and approved (including approval by the site’s IRB of record) before the modification is implemented.  All engaged participating sites will safeguard data, including secure transmission of data, as required by local information security policies.  All local site investigators conduct the study in accordance with applicable federal regulations and local laws.  All non-compliance with the study protocol or applicable requirements will reported in accordance with local policy  Describe the method for communicating to engaged participating sites (see “WORKSHEET: Communication and Responsibilities (HRP-830)”):   * Problems (inclusive of reportable events). * Interim results. * The closure of a study   If this is a multicenter study where you are a participating site/investigator, describe the local procedures for maintenance of confidentiality. (See “WORKSHEET: Communication and Responsibilities (HRP-830).”)   * Where and how data or specimens will be stored locally? * How long the data or specimens will be stored locally? * Who will have access to the data or specimens locally? * Who is responsible for receipt or transmission of the data or specimens locally? * How data and specimens will be transported locally? | **Yes** |